-
公开(公告)号：EP4087871A1
公开(公告)日：2022-11-16
申请号：EP21700010.8
申请日：2021-01-08
申请人： Biomunex Pharmaceuticals , Institut Curie , INSERM (Institut National de la Santé et de la Recherche Médicale)
发明人： LANTZ, Olivier , AMIGORENA, Sebastian , SAITAKIS, Michael , GUILLOT-DELOST, Maude , ZHUKOVSKY, Eugene , GERARD, Pierre-Emmanuel , FAROUDI, Mustapha
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , C07K16/22 , C07K16/32
-
公开(公告)号：EP4219688A1
公开(公告)日：2023-08-02
申请号：EP22215526.9
申请日：2019-12-18
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Assistance Publique-Hôpitaux de Paris (APHP) , Institut Curie , Université Paris Cité
IPC分类号： C12N5/0783 , C12N5/10 , A61K35/17 , A61P35/00 , A61P37/00
摘要： The present invention relates generally to immunotherapy, in particular immunotherapy for treating cancer, infectious diseases or autoimmune diseases. More specifically, the invention relates to Mucosal-Associated Invariant T (MAIT) cells expressing Chimeric Antigen Receptors (CARs), wherein the MAlT cell is allogenic with respect to the subject to be treated.
-
公开(公告)号：EP3898946A1
公开(公告)日：2021-10-27
申请号：EP19824315.6
申请日：2019-12-18
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de Paris , Assistance Publique-Hôpitaux de Paris (APHP) , Institut Curie
IPC分类号： C12N5/0783 , C12N5/10 , A61K35/17 , A61P35/00 , A61P37/00
-
公开(公告)号：EP3670667A1
公开(公告)日：2020-06-24
申请号：EP18306741.2
申请日：2018-12-19
申请人： Paris Sciences et Lettres - Quartier Latin , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , Institut Curie , The President and Fellows of Harvard College , HiFiBiO (HK) Limited , Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris
发明人： GRIFFITHS, Andrew , AMIGORENA, Sebastien , LANTZ, Olivier , WEITZ, David , NGHE, Philippe , GERARD, Annabelle
IPC分类号： C12Q1/6806 , C12N15/10
摘要： The invention concerns a method for identifying cognate pairs of a ligand species and a receptor species, comprising co-compartmentalising ligand species and receptor species to form a set of microreactors, each microreactor comprising at least one ligand species and preferably at least one receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when at least one ligand species and at least one receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that in a given subset of positive microreactors containing the same receptor species, the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species; and if the determined probability is greater than a predetermined threshold, identifying as a cognate pair the receptor species and the most frequent co-compartmentalized ligand species.
-
公开(公告)号：EP4234712A3
公开(公告)日：2023-09-27
申请号：EP23163171.4
申请日：2019-12-19
申请人： Paris Sciences et Lettres , Centre national de la recherche scientifique , Institut Curie , The President and Fellows of Harvard College , HiFiBiO (HK) Limited , Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
发明人： GRIFFITHS, Andrew , AMIGORENA, Sebastien , LANTZ, Olivier , WEITZ, David , GERARD, Annabelle , NGHE, Philippe
IPC分类号： C12Q1/6806 , C12N15/10
摘要： The invention concerns a method for identifying cognate pairs of a ligand species and a receptor species, comprising co-compartmentalising ligand species and receptor species to form a set of microreactors, each microreactor comprising at least one ligand species and preferably at least one receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when at least one ligand species and at least one receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that in a given subset of positive microreactors containing the same receptor species, the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species; and if the determined probability is greater than a predetermined threshold, identifying as a cognate pair the receptor species and the most frequent co-compartmentalized ligand species.
-
公开(公告)号：EP4234712A2
公开(公告)日：2023-08-30
申请号：EP23163171.4
申请日：2019-12-19
申请人： Paris Sciences et Lettres , Centre national de la recherche scientifique , Institut Curie , The President and Fellows of Harvard College , HiFiBiO (HK) Limited , Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
发明人： GRIFFITHS, Andrew , AMIGORENA, Sebastien , LANTZ, Olivier , WEITZ, David , GERARD, Annabelle , NGHE, Philippe
IPC分类号： C12Q1/6806 , C12N15/10
摘要： The invention concerns a method for identifying cognate pairs of a ligand species and a receptor species, comprising co-compartmentalising ligand species and receptor species to form a set of microreactors, each microreactor comprising at least one ligand species and preferably at least one receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when at least one ligand species and at least one receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that in a given subset of positive microreactors containing the same receptor species, the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species; and if the determined probability is greater than a predetermined threshold, identifying as a cognate pair the receptor species and the most frequent co-compartmentalized ligand species.
-
公开(公告)号：EP4149952A1
公开(公告)日：2023-03-22
申请号：EP21724332.8
申请日：2021-05-12
-
公开(公告)号：EP1504261B1
公开(公告)日：2008-08-13
申请号：EP03730020.9
申请日：2003-05-13
发明人： LANTZ, Olivier , TREINER, Emmanuel
IPC分类号： G01N33/48
CPC分类号： G01N33/505 , A01K2217/075 , A61K2035/122
摘要： The invention relates to methods of modulating an immune response in a mammal by modulating the activity of Jα33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising Jα33 T cells, MR1 polypeptide or a compound that modulates the activity of Jα33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said Jα33 T cells or MR1 polypeptide.
-
公开(公告)号：EP1504261A2
公开(公告)日：2005-02-09
申请号：EP03730020.9
申请日：2003-05-13
发明人： LANTZ, Olivier , TREINER, Emmanuel
IPC分类号： G01N33/48
CPC分类号： G01N33/505 , A01K2217/075 , A61K2035/122
摘要： The invention relates to methods of modulating an immune response in a mammal by modulating the activity of Jα33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising Jα33 T cells, MR1 polypeptide or a compound that modulates the activity of Jα33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said Jα33 T cells or MR1 polypeptide.
-
公开(公告)号：EP3899027A1
公开(公告)日：2021-10-27
申请号：EP19828270.9
申请日：2019-12-19
申请人： Paris Sciences et Lettres , Centre national de la recherche scientifique , Institut Curie , The President and Fellows of Harvard College , HiFiBiO (HK) Limited , Ecole Supérieure de Physique et de Chimie Industrielles de la Ville de Paris , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
发明人： GRIFFITHS, Andrew , AMIGORENA, Sebastien , LANTZ, Olivier , WEITZ, David , NGHE, Philippe , GERARD, Annabelle
IPC分类号： C12Q1/6806 , C12N15/10
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.02 秒)
